Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders (original) (raw)

• Kessler, R. C. et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62, 593–602 (2005).
  Article PubMed Google Scholar
• Fagiolini, A. et al. Functional impairment in the remission phase of bipolar disorder. Bipolar Disord. 7, 281–285 (2005).
  PubMed Google Scholar
• Huxley, N. & Baldessarini, R. J. Disability and its treatment in bipolar disorder patients. Bipolar Disord. 9, 183–196 (2007).
  PubMed Google Scholar
• Tohen, M. et al. The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am. J. Psychiatry 160, 2099–2107 (2003).
  PubMed Google Scholar
• Murray, C. J. & Lopez, A. D. Evidence-based health policy — lessons from the Global Burden of Disease Study. Science 274, 740–743 (1996).
  CAS PubMed Google Scholar
• Rush, A. J. et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163, 1905–1917 (2006).
  PubMed Google Scholar
• Trivedi, M. H. et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163, 28–40 (2006).
  PubMed Google Scholar
• Judd, L. L. et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry 59, 530–537 (2002).
  PubMed Google Scholar
• Nierenberg, A. A. et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am. J. Psychiatry 163, 210–216 (2006).
  PubMed Google Scholar
• Drevets, W. C. Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr. Opin. Neurobiol. 11, 240–249 (2001).
  CAS PubMed Google Scholar
• Dunlop, B. W. & Nemeroff, C. B. The role of dopamine in the pathophysiology of depression. Arch. Gen. Psychiatry 64, 327–337 (2007).
  CAS PubMed Google Scholar
• Manji, H. K., Drevets, W. C. & Charney, D. S. The cellular neurobiology of depression. Nature Med. 7, 541–547 (2001). This article reviews the data demonstrating that severe mood disorders arise from abnormalities in synaptic and neural-plasticity cascades.
  CAS PubMed Google Scholar
• Berman, R. M., Krystal, J. H. & Charney, D. S. in Biology of Schizophrenia and Affective Disease (ed. Watson, S. J.) 295–368 (American Psychiatric Press, Washington, D.C., 1996).
  Google Scholar
• Manji, H. K., Moore, G. J., Rajkowska, G. & Chen, G. Neuroplasticity and cellular resilience in mood disorders. Millennium Article. Mol. Psychiatry 5, 578–593 (2000).
  CAS PubMed Google Scholar
• Payne, J. L., Quiroz, J. A., Zarate, C. A. & Manji, H. K. Timing is everything: does the robust upregulation of noradrenergically regulated plasticity genes underlie the rapid antidepressant effects of sleep deprivation? Biol. Psychiatry 52, 921–926 (2002).
  CAS PubMed Google Scholar
• Orrego, F. & Villanueva, S. The chemical nature of the main central excitatory transmitter: a critical appraisal based upon release studies and synaptic vesicle localization. Neuroscience 56, 539–555 (1993).
  CAS PubMed Google Scholar
• Krystal, J. H. et al. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv. Rev. Psychiatry 7, 125–143 (1999).
  CAS PubMed Google Scholar
• Erecinska, M. & Silver, I. A. Metabolism and role of glutamate in mammalian brain. Prog. Neurobiol. 35, 245–296 (1990).
  CAS PubMed Google Scholar
• Varoqui, H., Schafer, M. K., Zhu, H., Weihe, E. & Erickson, J. D. Identification of the differentiation-associated Na+/PI transporter as a novel vesicular glutamate transporter expressed in a distinct set of glutamatergic synapses. J. Neurosci. 22, 142–155 (2002).
  CAS PubMed PubMed Central Google Scholar
• Herzog, E. et al. Localization of VGLUT3, the vesicular glutamate transporter type 3, in the rat brain. Neuroscience 123, 983–1002 (2004).
  CAS PubMed Google Scholar
• Peng, J. et al. Semiquantitative proteomic analysis of rat forebrain postsynaptic density fractions by mass spectrometry. J. Biol. Chem. 279, 21003–21011 (2004).
  CAS PubMed Google Scholar
• Rothstein, J. D., Jin, L., Dykes-Hoberg, M. & Kuncl, R. W. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc. Natl Acad. Sci. USA 90, 6591–6595 (1993).
  CAS PubMed PubMed Central Google Scholar
• Tanaka, K. et al. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 276, 1699–1702 (1997).
  CAS PubMed Google Scholar
• Pitt, D., Nagelmeier, THAT IS, Wilson, H. C. & Raine, C. S. Glutamate uptake by oligodendrocytes: Implications for excitotoxicity in multiple sclerosis. Neurology 61, 1113–1120 (2003).
  CAS PubMed Google Scholar
• Parsons, C. G., Danysz, W. & Quack, G. Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect. 11, 523–569 (1998).
  CAS PubMed Google Scholar
• Francis, P. T. Glutamatergic systems in Alzheimer's disease. Int. J. Geriatr Psychiatry 18, S15–S21 (2003).
  PubMed Google Scholar
• Cortese, B. M. & Phan, K. L. The role of glutamate in anxiety and related disorders. CNS Spectr. 10, 820–830 (2005).
  PubMed Google Scholar
• Fan, M. M. & Raymond, L. A. _N_-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog. Neurobiol. 81, 272–293 (2007).
  CAS PubMed Google Scholar
• Kim, J. S., Schmid-Burgk, W., Claus, D. & Kornhuber, H. H. Increased serum glutamate in depressed patients. Arch. Psychiatr. Nervenkr. 232, 299–304 (1982).
  CAS PubMed Google Scholar
• Altamura, C. A. et al. Plasma and platelet excitatory amino acids in psychiatric disorders. Am. J. Psychiatry 150, 1731–1733 (1993).
  CAS PubMed Google Scholar
• Mauri, M. C. et al. Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology 37, 124–129 (1998).
  CAS PubMed Google Scholar
• Mitani, H. et al. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 30, 1155–1158 (2006).
  CAS PubMed Google Scholar
• Levine, J. et al. Increased cerebrospinal fluid glutamine levels in depressed patients. Biol. Psychiatry 47, 586–593 (2000).
  CAS PubMed Google Scholar
• Frye, M. A., Tsai, G. E., Huggins, T., Coyle, J. T. & Post, R. M. Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. Biol. Psychiatry 61, 162–166 (2006).
  PubMed Google Scholar
• Francis, P. T. et al. Brain amino acid concentrations and Ca2+-dependent release in intractable depression assessed antemortem. Brain Res. 494, 315–324 (1989).
  CAS PubMed Google Scholar
• Altamura, C., Maes, M., Dai, J. & Meltzer, H. Y. Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Eur. Neuropsychopharmacol. 5, 71–75 (1995).
  CAS PubMed Google Scholar
• Maes, M., Verkerk, R., Vandoolaeghe, E., Lin, A. & Scharpe, S. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr. Scand. 97, 302–308 (1998).
  CAS PubMed Google Scholar
• Hashimoto, K., Sawa, A. & Iyo, M. Increased levels of glutamate in brains from patients with mood disorders. Biol. Psychiatry 62, 1310–1316 (2007).
  CAS PubMed Google Scholar
• de Graaf, R. A., Mason, G. F., Patel, A. B., Behar, K. L. & Rothman, D. L. _In vivo_1H-[13C]-NMR spectroscopy of cerebral metabolism. NMR Biomed. 16, 339–357 (2003).
  CAS PubMed Google Scholar
• Nowak, G., Ordway, G. A. & Paul, I. A. Alterations in the _N_-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res. 675, 157–164 (1995).
  CAS PubMed Google Scholar
• Scarr, E., Pavey, G., Sundram, S., MacKinnon, A. & Dean, B. Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder. Bipolar Disord. 5, 257–264 (2003).
  CAS PubMed Google Scholar
• McCullumsmith, R. E. et al. Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Res. 1127, 108–118 (2007). In this article, the authors describe alterations in NMDA receptor complex in post-mortem brain tissue of patients with BPD.
  CAS PubMed Google Scholar
• Law, A. J. & Deakin, J. F. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport 12, 2971–2974 (2001).
  CAS PubMed Google Scholar
• Nudmamud-Thanoi, S. & Reynolds, G. P. The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders. Neurosci. Lett. 372, 173–177 (2004).
  CAS PubMed Google Scholar
• Mundo, E. et al. Evidence that the _N_-methyl-D-aspartate subunit 1 receptor gene (GRIN1) confers susceptibility to bipolar disorder. Mol. Psychiatry 8, 241–245 (2003).
  CAS PubMed Google Scholar
• Martucci, L. et al. _N_-methyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: polymorphisms and mRNA levels. Schizophr. Res. 84, 214–221 (2006).
  PubMed Google Scholar
• Woo, T. U., Walsh, J. P. & Benes, F. M. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the _N_-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch. Gen. Psychiatry 61, 649–657 (2004). This article shows that there are alterations in neurons that express NMDA NR2A receptor subunits in post-mortem brain tissue of patients with BPD.
  CAS PubMed Google Scholar
• Meador-Woodruff, J. H., Hogg, A. J. Jr., & Smith, R. E. Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder. Brain Res. Bull. 55, 631–640 (2001).
  CAS PubMed Google Scholar
• Beneyto, M. & Meador-Woodruff, J. H. Lamina-specific abnormalities of AMPA receptor trafficking and signaling molecule transcripts in the prefrontal cortex in schizophrenia. Synapse 60, 585–598 (2006).
  CAS PubMed Google Scholar
• Kristiansen, L. V. & Meador-Woodruff, J. H. Abnormal striatal expression of transcripts encoding NMDA interacting PSD proteins in schizophrenia, bipolar disorder and major depression. Schizophr. Res. 78, 87–93 (2005).
  PubMed Google Scholar
• Clinton, S. M. & Meador-Woodruff, J. H. Abnormalities of the NMDA receptor and associated intracellular molecules in the thalamus in schizophrenia and bipolar disorder. Neuropsychopharmacology 29, 1353–1362 (2004).
  CAS PubMed Google Scholar
• Toro, C. & Deakin, J. F. NMDA receptor subunit NRI and postsynaptic protein PSD-95 in hippocampus and orbitofrontal cortex in schizophrenia and mood disorder. Schizophr. Res. 80, 323–330 (2005).
  PubMed Google Scholar
• Hamidi, M., Drevets, W. C. & Price, J. L. Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biol. Psychiatry 55, 563–569 (2004).
  PubMed Google Scholar
• Rajkowska, G. & Miguel-Hidalgo, J. J. Gliogenesis and glial pathology in depression. CNS Neurol. Disord. Drug Targets. 6, 219–233 (2007).
  CAS PubMed PubMed Central Google Scholar
• Ongur, D., Drevets, W. C. & Price, J. L. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc. Natl Acad. Sci. USA 95, 13290–13295 (1998). This article demonstrates that there is a reduction in the number of frontal cortex glia cells in mood disorders.
  CAS PubMed PubMed Central Google Scholar
• Rajkowska, G. et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol. Psychiatry 45, 1085–1098 (1999).
  CAS PubMed Google Scholar
• Miguel-Hidalgo, J. J. et al. Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder. Biol. Psychiatry 48, 861–873 (2000).
  CAS PubMed Google Scholar
• Rajkowska, G. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol. Psychiatry 48, 766–777 (2000).
  CAS PubMed Google Scholar
• Cotter, D., Mackay, D., Landau, S., Kerwin, R. & Everall, I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch. Gen. Psychiatry 58, 545–553 (2001).
  CAS PubMed Google Scholar
• Rajkowska, G., Halaris, A. & Selemon, L. D. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol. Psychiatry 49, 741–752 (2001).
  CAS PubMed Google Scholar
• Webster, M. J. et al. Immunohistochemical localization of phosphorylated glial fibrillary acidic protein in the prefrontal cortex and hippocampus from patients with schizophrenia, bipolar disorder, and depression. Brain Behav. Immunity 15, 388–400 (2001).
  CAS Google Scholar
• Bowley, M. P., Drevets, W. C., Ongur, D. & Price, J. L. Low glial numbers in the amygdala in major depressive disorder. Biol. Psychiatry 52, 404–412 (2002).
  PubMed Google Scholar
• Choudary, P. V. et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc. Natl Acad. Sci. USA 102, 15653–15658 (2005). A microarray study showing that there are alterations in glutamatergic and GABAergic systems in depression.
  CAS PubMed PubMed Central Google Scholar
• McCullumsmith, R. E. & Meador-Woodruff, J. H. Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder, and major depressive disorder. Neuropsychopharmacology 26, 368–375 (2002).
  CAS PubMed Google Scholar
• Zarate, C. A., Quiroz, J., Payne, J. & Manji, H. K. Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. Psychopharmacol. Bull. 36, 35–83 (2002).
  PubMed Google Scholar
• Kugaya, A. & Sanacora, G. Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr. 10, 808–819 (2005).
  PubMed Google Scholar
• Toro, C. T., Hallak, J. E., Dunham, J. S. & Deakin, J. F. Glial fibrillary acidic protein and glutamine synthetase in subregions of prefrontal cortex in schizophrenia and mood disorder. Neurosci. Lett. 404, 276–281 (2006).
  CAS PubMed Google Scholar
• Trullas, R. & Skolnick, P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur. J. Pharmacol. 185, 1–10 (1990). This article discusses the antidepressant-like activity of NMDA antagonists in preclinical models.
  CAS PubMed Google Scholar
• Sernagor, E., Kuhn, D., Vyklicky, L. Jr., & Mayer, M. L. Open channel block of NMDA receptor responses evoked by tricyclic antidepressants. Neuron 2, 1221–1227 (1989).
  CAS PubMed Google Scholar
• Pittaluga, A. et al. Antidepressant treatments and function of glutamate ionotropic receptors mediating amine release in hippocampus. Neuropharmacology 53, 27–36 (2007).
  CAS PubMed Google Scholar
• Nowak, G., Trullas, R., Layer, R. T., Skolnick, P. & Paul, I. A. Adaptive changes in the _N_-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. J. Pharmacol. Exp. Ther. 265, 1380–1386 (1993).
  CAS PubMed Google Scholar
• Paul, I. A., Layer, R. T., Skolnick, P. & Nowak, G. Adaptation of the NMDA receptor in rat cortex following chronic electroconvulsive shock or imipramine. Eur. J. Pharmacol. 247, 305–311 (1993).
  CAS PubMed Google Scholar
• Paul, I. A., Nowak, G., Layer, R. T., Popik, P. & Skolnick, P. Adaptation of the _N_-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J. Pharmacol. Exp. Ther. 269, 95–102 (1994).
  CAS PubMed Google Scholar
• Skolnick, P. et al. Adaptation of _N_-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 29, 23–26 (1996).
  CAS PubMed Google Scholar
• Nowak, G., Legutko, B., Skolnick, P. & Popik, P. Adaptation of cortical NMDA receptors by chronic treatment with specific serotonin reuptake inhibitors. Eur. J. Pharmacol. 342, 367–370 (1998).
  CAS PubMed Google Scholar
• Wong, M. L. et al. Differential effects of kindled and electrically induced seizures on a glutamate receptor (GluR1) gene expression. Epilepsy Res. 14, 221–227 (1993).
  CAS PubMed Google Scholar
• Naylor, P., Stewart, C. A., Wright, S. R., Pearson, R. C. & Reid, I. C. Repeated ECS induces GluR1 mRNA but not NMDAR1A-G mRNA in the rat hippocampus. Mol. Brain Res. 35, 349–353 (1996).
  CAS PubMed Google Scholar
• Svenningsson, P. et al. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc. Natl Acad. Sci. USA 99, 3182–3187 (2002).
  CAS PubMed PubMed Central Google Scholar
• Martinez-Turrillas, R., Del Rio, J. & Frechilla, D. Neuronal proteins involved in synaptic targeting of AMPA receptors in rat hippocampus by antidepressant drugs. Biochem. Biophys. Res. Commun. 353, 750–755 (2007).
  CAS PubMed Google Scholar
• Barbon, A. et al. Regulation of editing and expression of glutamate α-amino-propionic-acid (AMPA)/kainate receptors by antidepressant drugs. Biol. Psychiatry 59, 713–720 (2006).
  CAS PubMed Google Scholar
• Zarate, C. A. Jr, et al. Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann. NY Acad. Sci. 1003, 273–291 (2003).
  CAS PubMed Google Scholar
• Bowden, C. L. et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch. Gen. Psychiatry 57, 481–489 (2000).
  CAS PubMed Google Scholar
• Hokin, L. E., Dixon, J. F. & Los, G. V. A novel action of lithium: stimulation of glutamate release and inositol 1,4,5 trisphosphate accumulation via activation of the _N_-methyl D-aspartate receptor in monkey and mouse cerebral cortex slices. Adv. Enzyme Regul. 36, 229–244 (1996).
  CAS PubMed Google Scholar
• Nonaka, S., Hough, C. J. & Chuang, D. M. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting _N_-methyl-D-aspartate receptor-mediated calcium influx. Proc. Natl Acad. Sci. USA 95, 2642–2647 (1998).
  CAS PubMed PubMed Central Google Scholar
• Hashimoto, R., Hough, C., Nakazawa, T., Yamamoto, T. & Chuang, D. M. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J. Neurochem. 80, 589–597 (2002).
  CAS PubMed Google Scholar
• Du, J. et al. Structurally dissimilar antimanic agents modulate synaptic plasticity by regulating AMPA glutamate receptor subunit GluR1 synaptic expression. Ann. NY Acad. Sci. 1003, 378–380 (2003).
  CAS PubMed Google Scholar
• Du, J. et al. The role of hippocampal GluR1 and GluR2 receptors in manic-like behaviors. J. Neurosci. 28, 68–79 (2008).
  CAS PubMed PubMed Central Google Scholar
• Ahmad, S., Fowler, L. J. & Whitton, P. S. Effects of combined lamotrigine and valproate on basal and stimulated extracellular amino acids and monoamines in the hippocampus of freely moving rats. Naunyn Schmiedebergs Arch. Pharmacol. 371, 1–8 (2005).
  CAS PubMed Google Scholar
• Du, J. et al. The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology 32, 793–802 (2007).
  CAS PubMed Google Scholar
• Mizuta, I. et al. Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes. Neurosci. Lett. 310, 117–120 (2001).
  CAS PubMed Google Scholar
• Frizzo, M. E., Dall'Onder, L. P., Dalcin, K. B. & Souza, D. O. Riluzole enhances glutamate uptake in rat astrocyte cultures. Cell. Mol. Neurobiol. 24, 123–128 (2004).
  CAS PubMed Google Scholar
• Debono, M. W., Le Guern, J., Canton, T., Doble, A. & Pradier, L. Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur. J. Pharmacol. 235, 283–289 (1993).
  CAS PubMed Google Scholar
• Jehle, T. et al. Effects of riluzole on electrically evoked neurotransmitter release. Br. J. Pharmacol. 130, 1227–1234 (2000).
  CAS PubMed PubMed Central Google Scholar
• Zarate, C. A. Jr, et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am. J. Psychiatry 161, 171–174 (2004).
  PubMed Google Scholar
• Zarate, C. A. Jr, et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol. Psychiatry 57, 430–432 (2005).
  CAS PubMed Google Scholar
• Sanacora, G. et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol. Psychiatry 61, 822–825 (2007).
  CAS PubMed Google Scholar
• Crane, G. Cycloserine as an antidepressant agent. Am. J. Psychiatry 115, 1025–1026 (1959).
  CAS PubMed Google Scholar
• Crane, G. The psychotropic effect of cycloserine: a new use of an antibiotic. Comp. Psychiatry 2, 51–59 (1961).
  Google Scholar
• Heresco-Levy, U. et al. Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. J. Affect Disord. 93, 239–243 (2006).
  CAS Google Scholar
• van Berckel, B. N. et al. The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers. Psychopharmacology (Berl.) 138, 190–197 (1998).
  CAS Google Scholar
• van Berckel, B. N. et al. Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects. Neuropsychopharmacology 16, 317–324 (1997).
  CAS PubMed Google Scholar
• Davis, M., Ressler, K., Rothbaum, B. O. & Richardson, R. Effects of D-cycloserine on extinction: translation from preclinical to clinical work. Biol. Psychiatry 60, 369–375 (2006).
  CAS PubMed Google Scholar
• Ressler, K. J. et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch. Gen. Psychiatry 61, 1136–1144 (2004).
  PubMed Google Scholar
• Guastella, A. J. et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol. Psychiatry 63, 544–549 (2008).
  CAS PubMed Google Scholar
• Kushner, M. G. et al. D-Cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol. Psychiatry 62, 835–838 (2007).
  CAS PubMed Google Scholar
• Reisberg, B. et al. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch. Neurol. 63, 49–54 (2006).
  PubMed Google Scholar
• Reisberg, B. et al. Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 348, 1333–1341 (2003).
  CAS PubMed Google Scholar
• Teng, C. T. & Demetrio, F. N. Memantine may acutely improve cognition and have a mood stabilizing effect in treatment-resistant bipolar disorder. Rev. Bras. Psiquiatr. 28, 252–254 (2006).
  PubMed Google Scholar
• Zarate, C. A. Jr, et al. A randomized trial of an _N_-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63, 856–864 (2006). In this randomized, placebo-controlled, double-blind crossover study, ketamine, an NMDA receptor antagonist, was found to have long-lasting and sustained antidepressant effects that began minutes after its administration.
  CAS PubMed Google Scholar
• Ferguson, J. M. & Shingleton, R. N. An open-label, flexible-dose study of memantine in major depressive disorder. Clin. Neuropharmacol. 30, 136–144 (2007).
  CAS PubMed Google Scholar
• Harrison, N. L. & Simmonds, M. A. Quantitative studies on some antagonists of _N_-methyl D-aspartate in slices of rat cerebral cortex. Br. J. Pharmacol. 84, 381–391 (1985).
  CAS PubMed PubMed Central Google Scholar
• Zarate, C. A., Charney, D. S. & Manji, H. K. Searching for rational anti-_N_-methyl-D-aspartate treatment for depression. Arch. Gen. Psychiatry 64, 1100–1101 (2007).
  Google Scholar
• Moghaddam, B., Adams, B., Verma, A. & Daly, D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17, 2921–2927 (1997).
  CAS PubMed PubMed Central Google Scholar
• Maeng, S. et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry 63, 349–352 (2008).
  CAS PubMed Google Scholar
• Green, S. M. et al. Intravenous ketamine for pediatric sedation in the emergency department: safety profile with 156 cases. Acad. Emerg. Med. 5, 971–976 (1998).
  CAS PubMed Google Scholar
• Britt, G. C. & McCance-Katz, E. F. A brief overview of the clinical pharmacology of “club drugs”. Subst. Use Misuse 40, 1189–1201 (2005).
  PubMed Google Scholar
• Perry, E. B. Jr, et al. Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology (Berl.) 192, 253–260 (2007).
  CAS Google Scholar
• Carpenter, W. T. J. The schizophrenia ketamine challenge study debate. Biol. Psychiatry 46, 1081–1091 (1999).
  PubMed Google Scholar
• Berman, R. M. et al. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47, 351–354 (2000).
  CAS PubMed Google Scholar
• Bleakman, D. & Lodge, D. Neuropharmacology of AMPA and kainate receptors. Neuropharmacology 37, 1187–1204 (1998).
  CAS PubMed Google Scholar
• Borges, K. & Dingledine, R. AMPA receptors: molecular and functional diversity. Prog. Brain Res. 116, 153–170 (1998).
  CAS PubMed Google Scholar
• Black, M. D. Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. Psychopharmacology (Berl.) 179, 154–163 (2005).
  CAS Google Scholar
• Knapp, R. J. et al. Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. Eur. J. Pharmacol. 440, 27–35 (2002).
  CAS PubMed Google Scholar
• Li, X. et al. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 40, 1028–1033 (2001).
  CAS PubMed Google Scholar
• Bai, F., Bergeron, M. & Nelson, D. L. Chronic AMPA receptor potentiator (LY451646) treatment increases cell proliferation in adult rat hippocampus. Neuropharmacology 44, 1013–1021 (2003).
  CAS PubMed Google Scholar
• Lauterborn, J., Lynch, G., Vanderklish, P., Arai, A. & CM., G. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J. Neurosci. 20, 8–21 (2000).
  CAS PubMed PubMed Central Google Scholar
• Lauterborn, J. et al. Chronic elevation of brain-derived neurotrophic factor by ampakines. J. Pharmacol. Exp. Ther. 307, 297–305 (2003).
  CAS PubMed Google Scholar
• Suetake-Koga, S. et al. In vitro and antinociceptive profile of HON0001, an orally active NMDA receptor NR2B subunit antagonist. Pharmacol. Biochem. Behav. 84, 134–141 (2006).
  CAS PubMed Google Scholar
• Borza, I. et al. Selective NR1/2B _N_-methyl-D-aspartate receptor antagonists among indole-2-carboxamides and benzimidazole-2-carboxamides. J. Med. Chem. 50, 901–914 (2007).
  CAS PubMed Google Scholar
• Liverton, N. J. et al. Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective _N_-methyl-D-aspartate receptor antagonist. J. Med. Chem. 50, 807–819 (2007).
  CAS PubMed Google Scholar
• Preskorn, S. et al. A placebo-controlled trial of the NR2B subunit specific NMDA antagonist CP-101,606 plus paroxetine for treatment resistant depression (TRD). Annual Conference of the American Psychological Association (San Francisco, California) 154 (2007).
  Google Scholar
• Brown, R. H.,Jr. Amyotrophic lateral sclerosis — a new role for old drugs. N. Engl. J. Med. 352, 1376–1378 (2005).
  CAS PubMed Google Scholar
• Miller, T. M. & Cleveland, D. W. Medicine. Treating neurodegenerative diseases with antibiotics. Science 307, 361–362 (2005).
  CAS PubMed Google Scholar
• Rothstein, J. D. et al. β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433, 73–77 (2005).
  CAS PubMed Google Scholar
• Mineur, Y. S., Picciotto, M. R. & Sanacora, G. Antidepressant-like effects of ceftriaxone in male C57BL/6J mice. Biol. Psychiatry 61, 250–252 (2006).
  PubMed Google Scholar
• D'Ascenzo, M. et al. mGluR5 stimulates gliotransmission in the nucleus accumbens. Proc. Natl Acad. Sci. USA 104, 1995–2000 (2007).
  CAS PubMed PubMed Central Google Scholar
• Haydon, P. G. & Carmignoto, G. Astrocyte control of synaptic transmission and neurovascular coupling. Physiol. Rev. 86, 1009–1031 (2006).
  CAS PubMed Google Scholar
• Lee, Y., Gaskins, D., Anand, A. & Shekhar, A. Glia mechanisms in mood regulation: a novel model of mood disorders. Psychopharmacology (Berl.) 191, 55–65 (2007).
  Google Scholar
• Palucha, A. & Pilc, A. Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol. Ther. 115, 116–147 (2007).
  CAS PubMed Google Scholar
• Witkin, J. M., Marek, G. J., Johnson, B. G. & Schoepp, D. D. Metabotropic glutamate receptors in the control of mood disorders. CNS Neurol. Disord. Drug Targets. 6, 87–100 (2007).
  CAS PubMed Google Scholar
• Karasawa, J., Shimazaki, T., Kawashima, N. & Chaki, S. AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist. Brain Res. 1042, 92–98 (2005).
  CAS PubMed Google Scholar
• Patil, S. T. et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nature Med. 13, 1102–1107 (2007).
  CAS PubMed Google Scholar
• Dunayevich, E. et al. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 22 Aug 2007 (doi:10.1038/sj.npp.1301531).
  PubMed Google Scholar
• Bonanno, G. et al. Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J. Neurosci. 25, 3270–3279 (2005).
  CAS PubMed PubMed Central Google Scholar
• Wang, M., Yang, Y., Dong, Z., Cao, J. & Xu, L. NR2B-containing _N_-methyl-D-aspartate subtype glutamate receptors regulate the acute stress effect on hippocampal long-term potentiation/long-term depression in vivo. Neuroreport 17, 1343–1346 (2006).
  CAS PubMed Google Scholar
• Lesch, K. P. & Schmitt, A. Antidepressants and gene expression profiling: how to SNARE novel drug targets. Pharmacogenomics J. 2, 346–348 (2002).
  CAS PubMed Google Scholar
• Thompson, C. M. et al. Inhibitor of the glutamate vesicular transporter (VGLUT). Curr. Med. Chem. 12, 2041–2056 (2005).
  CAS PubMed Google Scholar
• Baker, D. A., Xi, Z. X., Shen, H., Swanson, C. J. & Kalivas, P. W. The origin and neuronal function of in vivo nonsynaptic glutamate. J. Neurosci. 22, 9134–9141 (2002).
  CAS PubMed PubMed Central Google Scholar
• Moran, M. M., McFarland, K., Melendez, R. I., Kalivas, P. W. & Seamans, J. K. Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J. Neurosci. 25, 6389–6393 (2005).
  CAS PubMed PubMed Central Google Scholar
• Lafleur, D. L. et al. _N_-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl.) 184, 254–256 (2006).
  CAS Google Scholar
• LaRowe, S. D. et al. Is cocaine desire reduced by _N_-acetylcysteine? Am. J. Psychiatry 164, 1115–1117 (2007).
  PubMed Google Scholar
• Carlson, P. J., Singh, J. B., Zarate, C. A. Jr, Drevets, W. C. & Manji, H. K. Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. NeuroRx 3, 22–41 (2006).
  CAS PubMed PubMed Central Google Scholar
• Du, J. et al. Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression. J. Neurosci. 24, 6578–6589 (2004).
  CAS PubMed PubMed Central Google Scholar
• Conn, P. J. Physiological roles and therapeutic potential of metabotropic glutamate receptors. Ann. NY Acad. Sci. 1003, 12–21 (2003).
  CAS PubMed Google Scholar
• Balazs, R., Bridges, R. J. & Cotman, C. W. Excitatory Amino Acid Transmission in Health and Disease (Oxford University Press, USA, New York, 2005).
  Google Scholar
• Hardingham, G. E., Fukunaga, Y. & Bading, H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nature Neurosci. 5, 405–414 (2002).
  CAS PubMed Google Scholar
• Ivanov, A. et al. Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular signal-regulated kinases (ERK) activity in cultured rat hippocampal neurons. J. Physiol. 572, 789–798 (2006).
  CAS PubMed PubMed Central Google Scholar
• Agid, Y. et al. How can drug discovery for psychiatric disorders be improved? Nature Rev. Drug Discov. 6, 189–201 (2007).
  CAS Google Scholar
• Michael-Titus, A. T., Bains, S., Jeetle, J. & Whelpton, R. Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex — a possible mechanism of neuroprotection in major depression? Neuroscience 100, 681–684 (2000).
  CAS PubMed Google Scholar
• White, G., Lovinger, D. M., Peoples, R. W. & Weight, F. F. Inhibition of _N_-methyl-D-aspartate activated ion current by desmethylimipramine. Brain Res. 537, 337–339 (1990).
  CAS PubMed Google Scholar
• Boyer, P. A., Skolnick, P. & Fossom, L. H. Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study. J. Mol. Neurosci. 10, 219–233 (1998).
  CAS PubMed Google Scholar
• Song, I. et al. Interaction of the _N_-ethylmaleimide-sensitive factor with AMPA receptors. Neuron 21, 393–400 (1998).
  CAS PubMed Google Scholar
• Stoll, L., Seguin, S. & Gentile, L. Tricyclic antidepressants, but not the selective serotonin reuptake inhibitor fluoxetine, bind to the S1S2 domain of AMPA receptors. Arch. Biochem. Biophys. 458, 213–219 (2007).
  CAS PubMed Google Scholar
• Moutsimilli, L. et al. Selective cortical VGLUT1 increase as a marker for antidepressant activity. Neuropharmacology 49, 890–900 (2005).
  CAS PubMed Google Scholar
• Tordera, R. M., Pei, Q. & Sharp, T. Evidence for increased expression of the vesicular glutamate transporter, VGLUT1, by a course of antidepressant treatment. J. Neurochem. 94, 875–883 (2005).
  CAS PubMed Google Scholar
• Dixon, J. F., Los, G. V. & Hokin, L. E. Lithium stimulates glutamate “release” and inositol 1,4,5-trisphosphate accumulation via activation of the _N_-methyl-D-aspartate receptor in monkey and mouse cerebral cortex slices. Proc. Natl Acad. Sci. USA 91, 8358–8362 (1994).
  CAS PubMed PubMed Central Google Scholar
• Dixon, J. F. & Hokin, L. E. Lithium stimulates accumulation of second-messenger inositol 1,4,5-trisphosphate and other inositol phosphates in mouse pancreatic minilobules without inositol supplementation. Biochem. J. 304, 251–258 (1994).
  CAS PubMed PubMed Central Google Scholar
• Ma, J. & Zhang, G. Y. Lithium reduced _N_-methyl-D-aspartate receptor subunit 2A tyrosine phosphorylation and its interactions with Src and Fyn mediated by PSD-95 in rat hippocampus following cerebral ischemia. Neurosci. Lett. 348, 185–189 (2003).
  CAS PubMed Google Scholar
• Karkanias, N. B. & Papke, R. L. Lithium modulates desensitization of the glutamate receptor subtype gluR3 in Xenopus oocytes. Neurosci. Lett. 277, 153–156 (1999).
  CAS PubMed Google Scholar
• Kang, T. C. et al. Valproic acid reduces enhanced vesicular glutamate transporter immunoreactivities in the dentate gyrus of the seizure prone gerbil. Neuropharmacology 49, 912–921 (2005).
  CAS PubMed Google Scholar
• Cunningham, M. O., Woodhall, G. L. & Jones, R. S. Valproate modifies spontaneous excitation and inhibition at cortical synapses in vitro. Neuropharmacology 45, 907–917 (2003).
  CAS PubMed Google Scholar
• Ueda, Y. & Willmore, L. J. Molecular regulation of glutamate and GABA transporter proteins by valproic acid in rat hippocampus during epileptogenesis. Exp. Brain Res. 133, 334–339 (2000).
  CAS PubMed Google Scholar
• Hassel, B., Iversen, E. G., Gjerstad, L. & Tauboll, E. Up-regulation of hippocampal glutamate transport during chronic treatment with sodium valproate. J. Neurochem. 77, 1285–1292 (2001).
  CAS Google Scholar
• Loscher, W. Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain. Neurochem. Res. 18, 485–502 (1993).
  CAS PubMed Google Scholar
• Zeise, M. L., Kasparow, S. & Zieglgansberger, W. Valproate suppresses _N_-methyl-D-aspartate-evoked, transient depolarizations in the rat neocortex in vitro. Brain Res. 544, 345–348 (1991).
  CAS PubMed Google Scholar
• Ko, G. Y., Brown-Croyts, L. M. & Teyler, T. J. The effects of anticonvulsant drugs on NMDA-EPSP, AMPA-EPSP, and GABA-IPSP in the rat hippocampus. Brain Res. Bull. 42, 297–302 (1997).
  CAS PubMed Google Scholar
• Turski, L. The _N_-methyl-D-aspartate receptor complex. Various sites of regulation and clinical consequences. Arzneimittelforschung 40, 511–514 (1990) (in German).
  CAS PubMed Google Scholar
• Steppuhn, K. G. & Turski, L. Modulation of the seizure threshold for excitatory amino acids in mice by antiepileptic drugs and chemoconvulsants. J. Pharmacol. Exp. Ther. 265, 1063–1070 (1993).
  CAS PubMed Google Scholar
• Kunig, G. et al. Inhibition of [3H]α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid [AMPA] binding by the anticonvulsant valproate in clinically relevant concentrations: an autoradiographic investigation in human hippocampus. Epilepsy Res. 31, 153–157 (1998).
  CAS PubMed Google Scholar
• Basselin, M., Chang, L., Bell, J. M. & Rapoport, S. I. Chronic lithium chloride administration attenuates brain NMDA receptor-initiated signaling via arachidonic acid in unanesthetized rats. Neuropsychopharmacology 31, 1659–1674 (2006).
  CAS PubMed Google Scholar
• Zarate, C. A. J. et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am. J. Psychiatry 163, 153–155 (2006).
  PubMed Google Scholar